Advances in Mitochondrial Dysfunction and Its Role in Cardiovascular Diseases
Yan Qiu1, Shuo Chang1,2, Ye Zeng3
1Department of Cardiovascular Surgery, Fuwai Yunnan Hospital, Chinese Academy of Medical Sciences, Affiliated Cardiovascular Hospital of Kunming Medical University, Kunming 650102, China.
Insights
Mitochondrial dysfunction is key in cardiovascular diseases (CVDs), impacting energy, stress, and quality control. Targeting mitochondria offers new therapeutic avenues for CVD management.
Area of Science:
- Mitochondrial biology
- Cardiovascular pathophysiology
- Translational medicine
Background:
- Cardiovascular diseases (CVDs) are a leading cause of death globally.
- Complex mechanisms beyond traditional risk factors drive CVD progression.
- Mitochondrial dysfunction is increasingly recognized as a central player in CVD pathogenesis.
Purpose of the Study:
- To synthesize current knowledge on mitochondrial dysfunction in CVD.
- To explore the link between mitochondrial dysregulation and CVD progression.
- To evaluate mitochondria-targeted therapeutic strategies for CVD.
Main Methods:
- Comprehensive literature review of recent research.
- Focus on mitochondrial energy metabolism, membrane potential, and dynamics (fusion/fission, mitophagy, biogenesis).
- Critical evaluation of pharmacological, gene, and regenerative therapies.
Main Results:
- Mitochondrial dysfunction contributes to endothelial dysfunction, myocardial injury, and cardiac remodeling.
- Dysregulation in energy metabolism, membrane potential, and dynamics are implicated.
- Emerging therapies target mitochondria to address CVD.
Conclusions:
- Understanding mitochondrial mechanisms in CVD is crucial for developing novel diagnostic biomarkers and precision therapeutics.
- Targeting mitochondria presents significant translational challenges and opportunities for transforming CVD management.
- Bridging mitochondrial biology and clinical cardiology is essential for future advancements.
Abstract:
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide and is attributed to complex pathophysiological mechanisms that surpass the traditional risk factors. Emerging evidence indicates that mitochondrial dysfunction plays a central role in CVD progression, linking impaired bioenergetics, oxidative stress imbalance, and defective mitochondrial quality control to endothelial dysfunction, myocardial injury, and adverse cardiac remodeling. However, the mechanistic interplay between mitochondrial dysfunction and CVD pathogenesis remains unclear. This review provides a comprehensive synthesis of recent knowledge, focusing on the dysregulation of mitochondrial energy metabolism, alterations in mitochondrial membrane potential, and disruptions in mitochondrial dynamics, including the balance of fusion and fission, mitophagy, and biogenesis. Furthermore, we critically evaluated emerging mitochondria-targeted therapeutic strategies, including pharmacological agents, gene therapies, and regenerative approaches. By bridging fundamental mitochondrial biology with clinical cardiology, this review underscores the critical translational challenges and opportunities in developing mitochondria-focused interventions. A deeper understanding of the mitochondrial mechanisms in CVD pathophysiology will offer novel diagnostic biomarkers and precision-targeted therapeutics, thereby transforming CVD management.
Related Concept Videos
Mitochondrial Membranes
Coronary Artery Disease I: Introduction
Mitochondria
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Pathophysiology of Heart Failure
Cardiomyopathy II: Dilated Cardiomyopathy


